It has been reported that Novo Nordisk may have inadvertently allowed generics of its GLP-1 agonist semaglutide, the active ingredient in diabetes therapy Ozempic and obesity drug Wegovy, into the ...

The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems, providing an alternative to comparator products and lowering price ...

December 31, 2025 • A few years back, many politicians were raising the alarm about the dangers of "CRT" in schools. Today, the new risk to public education is "DEI." What do both of these moments ...

What's CODE SWITCH? It's the fearless conversations about race that you've been waiting for. Hosted by journalists of color, our podcast tackles the subject of race with empathy and humor. We explore ...

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...

In 2026, Novo Nordisk’s patent on semaglutide will expire in several countries, including India and China. Generic-drug makers are poised to flood these markets with inexpensive products. Industry ...